MA
NVO

MJP Associates’s Novo Nordisk NVO Stock Holding History

MJP Associates’s Portfolio NVO Stock Details NVO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		– Sell
-6,764
Closed -$344K – 263
2025
Q4 		$344K Sell
6,764
-777
-10% -$39.7K 0.04% 176
2025
Q3 		$418K Buy
7,541
+2,270
+43% +$133K 0.06% 153
2025
Q2 		$364K Buy
5,271
+1,613
+44% +$110K 0.05% 158
2025
Q1 		$254K Sell
3,658
-1,387
-27% -$115K 0.05% 180
2024
Q4 		$434K Sell
5,045
-787
-13% -$85.1K 0.08% 129
2024
Q3 		$694K Buy
5,832
+969
+20% +$129K 0.13% 83
2024
Q2 		$694K Buy
4,863
+398
+9% +$52.7K 0.14% 80
2024
Q1 		$573K Buy
4,465
+583
+15% +$69.4K 0.12% 88
2023
Q4 		$402K Buy
3,882
+77
+2% +$7.62K 0.11% 92
2023
Q3 		$346K Buy
+3,805
New +$335K 0.1% 89

Other funds holding NVO

Dodge & Cox
Dodge & Cox San Francisco, California $182B AUM 14.68% 1-Year Est. Return
Loomis, Sayles & Company
Loomis, Sayles & Company Boston, Massachusetts $74.3B AUM 24.01% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return
Capital International Investors
Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return
Susquehanna International Group
Susquehanna International Group Bala Cynwyd, Pennsylvania $893B AUM 36.07% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
DAM
Diamant Asset Management Ridgefield, Connecticut $137B AUM 18.02% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return
F
Folketrygdfondet Oslo Norway, Norway $5.64B AUM 47.16% 1-Year Est. Return

MJP Associates's NVO Position: Q1 2026 in Review

MJP Associates sold out of Novo Nordisk (NVO) in Q1 2026, closing a stake of 6,764 shares — an estimated $344K sold.

MJP Associates first reported a position in NVO in Q3 2023 and held it in 10 quarters. The position peaked at $694K in Q3 2024. 1,272 funds tracked by Wall St. Rank hold NVO as of Q1 2026.

  • MJP Associates reported no remaining Novo Nordisk position as of Q1 2026 after selling out during the quarter.
  • MJP Associates sold 6,764 Novo Nordisk shares in Q1 2026, an estimated $344K.
  • MJP Associates first reported a position in Novo Nordisk in Q3 2023 and held it in 10 quarters.
  • MJP Associates's Novo Nordisk position peaked at $694K in Q3 2024.
  • 1,272 funds tracked by Wall St. Rank held Novo Nordisk as of Q1 2026.

Based on MJP Associates's 13F filing for Q1 2026, filed 5 May 2026.